Managing proliferative diabetic retinopathy (PDR) in patients with a history of eye surgery requires a nuanced understanding of how prior surgical interventions alter ocular anatomy, healing responses, and disease progression. While PDR itself is a vision-threatening complication of diabetes, the presence of previous procedures—such as cataract extraction, vitrectomy, laser photocoagulation, or glaucoma surgery—can significantly affect diagnostic accuracy, treatment efficacy, and surgical risk. This expanded guide provides clinicians with a comprehensive framework for evaluating and treating these complex patients, grounded in current evidence and practical clinical reasoning.

Pathophysiology of PDR in Eyes with Prior Surgery

Proliferative diabetic retinopathy is defined by retinal ischemia that triggers upregulation of vascular endothelial growth factor (VEGF) and other cytokines, leading to neovascularization on the optic disc, retina, and iris. In eyes that have undergone previous surgery, several factors can modify this process. Vitrectomy, for instance, removes the vitreous scaffold that supports new vessel growth, but it also disrupts the blood–retinal barrier and may accelerate cataract formation or induce inflammation, which can paradoxically worsen PDR progression in some patients. Prior laser photocoagulation destroys ischemic retina, reducing VEGF production, but repeated treatments can cause cumulative retinal damage, chorioretinal scarring, and visual field deficits. Glaucoma filtering surgeries alter intraocular pressure dynamics and may lead to hypotony or inflammation, both of which can exacerbate diabetic retinopathy. Understanding these pathophysiological interactions is critical when planning management.

Preoperative Assessment

Before initiating any treatment, a thorough preoperative assessment is essential. This should include:

  • Detailed ocular history: Type and date of prior surgeries, any complications (e.g., postoperative endophthalmitis, retinal detachment, persistent inflammation), baseline visual acuity, intraocular pressure trends, and lens status.
  • Comprehensive medical history: Duration of diabetes, glycemic control (HbA1c), blood pressure, lipid levels, renal function, and use of anticoagulants or antiplatelet agents that may influence bleeding risk during surgery or injection.
  • Slit-lamp and fundus examination: Evaluate for neovascularization on the iris (NVI) or anterior chamber angle (NVA), vitreous hemorrhage, tractional retinal detachment, and macular edema. Assess the vitreous: in pseudophakic or aphakic eyes, vitreous prolapse into the anterior chamber may be present, complicating laser or injection.
  • Imaging: Optical coherence tomography (OCT) of the macula to detect subretinal fluid, intraretinal cysts, or vitreomacular traction. Fluorescein angiography (FA) remains invaluable for identifying areas of nonperfusion, neovascular fronds, and leakage. Widefield imaging can capture peripheral ischemia. B-scan ultrasonography is indicated if media opacity prevents visualization of the posterior segment.
  • Gonioscopy: Rule out neovascular glaucoma (NVG), which is more common in eyes with prior surgery due to breakdown of the blood–aqueous barrier. Angle closure or synechiae may preclude certain treatments.

Special attention should be paid to patients with a history of vitrectomy, as the lack of vitreous can alter the distribution of intravitreal anti-VEGF agents and affect the efficacy of laser. In pseudophakic eyes, posterior capsule opacification may mimic or obscure vitreous hemorrhage. In glaucoma-filtered eyes, bleb status must be assessed to avoid bleb trauma during laser or injection.

Management Strategies

The management of PDR in post-surgical eyes often requires a multimodal approach that combines medical, laser, and surgical therapies. The choice and sequence of treatments depend on the severity of PDR, the type of prior surgery, the presence of complications, and the patient’s systemic health.

Anti-VEGF Therapy

Intravitreal anti-VEGF injections (e.g., ranibizumab, aflibercept, bevacizumab) are first-line for many cases of PDR, especially when neovascularization is active, macular edema is present, or laser is contraindicated. In eyes with prior vitrectomy, drug clearance is accelerated, so more frequent injections may be needed to maintain suppression of VEGF. Studies have shown that anti-VEGF can effectively regress neovascularization even in vitrectomized eyes, but the dosing interval may need to be shortened (e.g., every 2–4 weeks instead of monthly). In pseudophakic eyes, careful injection technique is required to avoid damaging the intraocular lens or causing vitreous wick into the injection site. For patients with a history of glaucoma surgery, avoid injecting directly over a bleb to prevent bleb leak or infection.

Laser Therapy

Panretinal photocoagulation (PRP) remains a standard treatment for PDR, but its application must be modified after prior surgery. After vitrectomy, the endpoint of PRP—visible white–burn at the retina—may be harder to achieve due to media clarity changes and the presence of gas or silicone oil. Additionally, the lack of vitreous means that laser effects on the retina may be more profound, raising the risk of exudative retinal detachment or choroidal effusion. In eyes with previous PRP, careful mapping is needed to avoid overtreatment and to spare residual viable retina. Focal or grid laser may still be used for clinically significant macular edema, but anti-VEGF is generally preferred in post-cataract eyes where laser can exacerbate cystoid macular edema.

Surgical Interventions

Vitrectomy is indicated for nonclearing vitreous hemorrhage (typically >1 month despite medical therapy), tractional retinal detachment threatening the macula, or refractory neovascular glaucoma. Prior eye surgery can influence surgical planning in several ways:

  • Port placement: In pseudophakic eyes, sclerotomies should be placed away from the lens implant and any posterior capsule opening. In aphakic eyes or those with posterior capsule defects, care must be taken to avoid vitreous incarceration at sclerotomy sites.
  • Adjunctive agents: Endolaser or cryopexy may be used to treat ischemic retina. In eyes with prior laser, residual peripheral retina may be thin, requiring reduced laser energy to avoid retinal breaks. Anti-VEGF can be injected intraoperatively to reduce intraoperative bleeding and postoperative recurrence.
  • Gas or oil tamponade: The choice of tamponade depends on retinal status and history of prior gas use; silicone oil may be needed for recurrent retinal detachment, but it can complicate future anti-VEGF injections and has higher rates of glaucoma and corneal decompensation, especially in diabetics with already compromised endothelium.
  • Phacoemulsification with vitrectomy: Combined cataract surgery and vitrectomy is common but introduces risks: increased inflammation, posterior capsule rupture, and protracted recovery. In patients with preexisting diabetic macular edema, preoperative anti-VEGF is recommended to stabilize the macula.

Combination Approaches

Many patients benefit from sequential or concurrent therapies. For example, anti-VEGF injections can be initiated to reduce neovascular activity and prepare the eye for safer PRP. After laser, sustained anti-VEGF may be needed to prevent recurrence, especially in eyes with high-risk NVG. In some cases, long-acting steroid implants (e.g., dexamethasone) are used for refractory diabetic macular edema in pseudophakic eyes, but steroids can raise intraocular pressure and worsen cataract in phakic patients, so careful monitoring is required.

Considerations for Specific Prior Surgeries

Cataract Surgery

Post-cataract PDR management is complicated by pseudophakia, posterior capsule opacification (PCO), and increased risk of macular edema. PCO can obscure laser delivery and visualization of retinal neovascularization; Nd:YAG capsulotomy may be needed before treatment, but this carries risks of cystoid macular edema and vitreous disturbance in diabetics. Anti-VEGF injections are often preferred over laser for macular edema because laser can exacerbate inflammation. When PRP is necessary, reduced power settings should be used to avoid capsular damage. Vision-threatening complications like endophthalmitis are higher in diabetics after cataract surgery, so strict sterile technique and prompt treatment of any infection are essential.

Glaucoma Surgery

Patients with prior trabeculectomy or tube shunt implants require special caution. Antimetabolite use in glaucoma surgery increases the risk of bleb leak and infection; therefore, intravitreal injections should be performed away from the bleb (typically in the superotemporal quadrant if the bleb is superior) using a sterile speculum and povidone-iodine. Elevated IOP from neovascular glaucoma can be treated with anti-VEGF to regress angle neovascularization, followed by PRP if needed. In eyes with preexisting filtration surgery, hypotony can occur after vitrectomy or PRP due to ciliary body shutdown; close IOP monitoring is critical.

Vitrectomy

As noted, vitrectomized eyes clear anti-VEGF drugs faster, require more frequent injections, and may have increased risk of retinal detachment post-injection if a vitreous wick is created. PRP is more challenging because of media clarity and the absence of vitreous support; however, endolaser can be applied at the time of surgery. Silicone oil–filled eyes present unique obstacles: intravitreal injections displace oil and can cause emulsion, so sub-Tenon’s or suprachoroidal delivery may be considered. Post-vitrectomy diabetic eyes also have higher rates of rubeosis iridis, so vigilant anterior segment examination is mandatory.

Retinal Laser or Cryotherapy

Patients who have had previous PRP may have extensive chorioretinal scars, which reduce the retina’s capacity for further laser without causing thermal damage to the optic nerve or macula. In such cases, anti-VEGF therapy is often the primary strategy. Cryotherapy is rarely used today but may still be encountered in older patients; it can cause significant inflammation and should be avoided in PDR when possible.

Postoperative Care and Long-Term Follow-Up

Close monitoring is paramount after any intervention. Follow-up visits should include:

  • Visual acuity and IOP measurement at each visit.
  • Slit-lamp examination for anterior chamber inflammation, neovascularization of the iris/angle, and lens status (in phakic patients).
  • Dilated fundus examination with attention to vitreous hemorrhage, retinal neovascularization, and macular edema.
  • OCT to quantify macular thickness and assess for subtle fluid.
  • FA or widefield imaging every 3–6 months in high-risk patients to guide treatment decisions.

After vitrectomy, patients may develop accelerated cataract progression or posterior capsule opacification; if vision is compromised, cataract surgery should be considered but with careful preoperative stabilization of PDR and DME. In patients with NVG, IOP control may require a combination of topical medications, anti-VEGF, and cyclodestructive procedures. Long-term systemic risk factor management (glycemic control, blood pressure, lipids) is essential to reduce the need for repeated interventions.

Complications and Their Management

Common complications in this population include:

  • Recurrent vitreous hemorrhage: Managed with anti-VEGF, PRP, or repeat vitrectomy. In post-vitrectomy eyes, hemorrhage often originates from fibrovascular proliferation at sclerotomy sites.
  • Tractional retinal detachment: Surgical repair may require membrane peeling, endolaser, and gas or oil tamponade. The presence of prior glaucoma surgery complicates postoperative IOP control.
  • Neovascular glaucoma: Urgent panretinal photocoagulation and anti-VEGF therapy are first-line; tube shunt surgery may be necessary if angle closure persists.
  • Endophthalmitis: Higher risk in diabetics, especially those with blebs or recent surgery; prompt vitreous tap and intravitreal antibiotics are critical.
  • Macular edema: May worsen after PRP or cataract surgery; treated with anti-VEGF or steroids.
  • Hypotony: Can follow vitrectomy, PRP (shutdown of ciliary body), or glaucoma surgery; managed with observation, anti-inflammatory therapy, or surgical revision in persistent cases.

Role of Systemic Control

No amount of ocular treatment will be effective without rigorous systemic management. Optimizing glycemic control (HbA1c <7% in nonhypoglycemic-prone patients), blood pressure (target <130/80 mmHg), and lipids (statin therapy) reduces the risk of PDR progression and improves outcomes after eye surgery. Smoking cessation and regular exercise are also beneficial. Inadequate systemic control is the single most common cause of treatment failure in PDR.

Emerging Therapies and Future Directions

Newer anti-VEGF agents with extended duration (e.g., faricimab) may reduce injection burden in post-surgical eyes. Sustained-release intravitreal implants (e.g., ranibizumab port delivery system) are being studied in PDR but have not yet been widely adopted for complex cases. Improved imaging technologies—such as OCT angiography (OCTA)—allow noninvasive visualization of neovascular networks and could help guide treatment without repeated FA. Additionally, advances in vitrectomy instrumentation (wide-angle viewing systems, small-gauge cutters) have improved safety for patients with prior surgeries. Research into potential treatments targeting the angiopoietin pathway and novel laser delivery methods (e.g., navigated laser, micropulse laser) may further refine management in the future.

Conclusion

Managing proliferative diabetic retinopathy in patients with a history of eye surgery demands a personalized, multi-modal strategy that respects altered anatomy, variable drug kinetics, and increased complication risks. A thorough preoperative evaluation, tailored use of anti-VEGF agents and laser, careful surgical planning when vitrectomy is needed, and vigilant long-term follow-up are the cornerstones of success. Systemic control remains the foundation of any treatment plan. By integrating these principles, clinicians can help preserve vision and improve quality of life in this challenging patient population.